Kymera Therapeutics (KYMR) Stock Statistics & Valuation Metrics

Kymera Therapeutics has a market cap or net worth of $2.29B. The enterprise value is $2.82B.

Kymera Therapeutics has 64,944,140 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kymera Therapeutics’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -28.33%.

The current PE Ratio of Kymera Therapeutics is -13.49. Kymera Therapeutics’s PEG ratio is -0.74.

In the last 12 months, Kymera Therapeutics had revenue of 47.07M and earned -223.86M in profits. Earnings per share was -2.98.

In the last 12 months, operating cash flow was -194.50M and capital expenditures -12.84M, giving a free cash flow of -207.34M billion.

Kymera Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Kymera Therapeutics upcoming earnings date is May 9, 2025, TBA Not Confirmed.

Kymera Therapeutics as a current ratio of 7.53, with Debt / Equity ratio of 10.50%

In the past 12 months, Kymera Therapeutics has paid 0.00 in taxes.

Kymera Therapeutics EV to EBITDA ratio is -13.81, with an EV/FCF ratio of -14.40.

Kymera Therapeutics has $488.74M in cash and marketable securities with $87.76M in debt, giving a net cash position of -$400.98M billion.

Gross margin is 88.53%, with operating margin of -555.82%, and net profit margin of -475.57%.

The average price target for Kymera Therapeutics is $55.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy